Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03554356 · ClinicalTrials.gov registry record · NA
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
A NA study of Barrett Esophagus and Intestinal Metaplasia, sponsored by University of North Carolina, Chapel Hill.
- Active
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 11
- Study locations
NCT03554356: Active NA study of Barrett Esophagus and Intestinal Metaplasia, sponsored by University of North Carolina, Chapel Hill.
NCT03554356 is a NA study of Barrett Esophagus and Intestinal Metaplasia that is active but no longer recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 70 participants, below the 3,563-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (98% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03554356, a NA study of Barrett Esophagus and Intestinal Metaplasia, is active but no longer recruiting, sponsored by University of North Carolina, Chapel Hill.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 11
- Study locations
Study Summary
A multicenter, prospective, single arm, non randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more radiofrequency ablations (RFA) for dysplastic BE, or \<50% eradication of Barrett's Esophagus (BE) after 2 RFA treatments.
Conditions Studied
Interventions
- DEVICE CryoBalloon Focal Ablation System
Study Locations (11)
New York
- Northwell Health - Lake Success
- Columbia University - New York
Alabama
- University of Alabama at Birmingham - Birmingham
District of Columbia
- Georgetown University - Washington D.C.
Maryland
- Johns Hopkins University - Baltimore
Minnesota
- Mayo Clinic Rochester - Rochester
North Carolina
- UNC Chapel Hill - Chapel Hill
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Pennsylvania
- Geisinger Clinic - Danville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2027-08 |
| Phase | NA |
What the registry record for NCT03554356 still lists
NCT03554356 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 3,563-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Barrett Esophagus appearing as the primary indexed condition, and to 1 intervention - of which CryoBalloon Focal Ablation System is the first listed.
NCT03554356 lists 11 locations in 10 states (New York, Alabama, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT03554356 about?
NCT03554356 is a clinical study titled "Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)". A multicenter, prospective, single arm, non randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more radiofrequency ablations (RFA...
What is the current status of trial NCT03554356?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2018-09-04. Estimated completion is 2027-08.
What conditions does trial NCT03554356 study?
This clinical trial studies the following conditions: Barrett Esophagus, Intestinal Metaplasia, Esophageal Dysplasia.
What interventions are being tested in trial NCT03554356?
The interventions under investigation include: CryoBalloon Focal Ablation System (DEVICE).
Who is sponsoring clinical trial NCT03554356?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03554356 being conducted?
This trial has 11 study locations across Alabama, District of Columbia, Maryland, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Barrett Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03554356's enrollment target sits among peer trials
70 23rd of 32 higher than 10 of 32 other Barrett Esophagus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Barrett Esophagus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
RECRUITING · NA
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
RECRUITING · NA
-
Pilot Study for OCT Guided In Vivo Laser Capture Microdissection for Assessing the Prognosis of Barrett's Esophagus
RECRUITING · NA
-
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI